

vaccine is capable of inducing an immune response in a patient. Again, the response may be one or more of a T-helper cell response, a cytotoxic T-cell response, an NK cell response and/or an immune response.

In a further aspect, the present invention provides the use of 791Tgp72 antigen or a polypeptide of the CD55 family, or a fragment or derivative of 791Tgp72 or of a polypeptide of the CD55 family, in the preparation of a medicament for the treatment of cancer.

In a further aspect, the present invention provides the use of nucleic acid encoding 791Tgp72 antigen or a polypeptide of the CD55 family, or a fragment or derivative of 791Tgp72 or of a polypeptide of the CD55 family, in the preparation of a medicament for the treatment of cancer. --

In the Claims:

Please amend claims 1, 2, 4-7, 13, 14, 27, 31 and 32 as follows:

- C 2
Sub
J, 1
1. (Amended) A cancer vaccine comprising a fragment of a polypeptide of the CD55 family or a derivative thereof, wherein said fragment or derivative contains a T cell epitope, and wherein the vaccine is capable of inducing an immune response in a patient, said immune response being a T cell response.

2. (Amended) A cancer vaccine according to claim 1 wherein the fragment or derivative is of 791Tgp72 antigen.

4. (Twice amended) A cancer vaccine according to claim 1 wherein the fragment or derivative has part of the amino acid sequence of Fig. 10.

5. (Twice amended) A cancer vaccine according to claim 1 wherein the fragment or derivative includes part or all of the amino acid sequence consisting of amino acids 97-159 of Fig. 10.

C3
D2
6. (Twice amended) A cancer vaccine according to claim 5 wherein the fragment or derivative includes a sequence having at least five amino acids identical with corresponding amino acids of a contiguous stretch of seven amino acids contained within amino acids 121-128 or 151-158 of Fig. 10.

7. (Twice amended) A cancer vaccine according to claim 1 wherein the fragment or derivative includes a sequence having at least six amino acids identical with corresponding amino acids of a contiguous stretch of nine amino acids contained within amino acids 83-93 of Fig. 10.

C4^{sub} 13. (Twice amended) A cancer vaccine comprising a nucleic acid molecule which encodes a fragment or derivative as specified in claim 1, wherein the vaccine is capable of inducing an immune response in a patient, said immune response being a T cell response.

sub 14. (Amended) A cancer vaccine according to claim 13 having part of a nucleic acid sequence as shown in Fig. 10 or Fig. 11.

C5 27. (Amended) A cancer vaccine according to claim 2, wherein the antigen has part of the amino acid sequence of Fig. 10.

C6 31. (Amended) A cancer vaccine comprising a nucleic acid molecule which encodes an antigen as specified in claim 2, wherein the vaccine is capable of inducing an immune response in a patient, said immune response being a T cell response.

32. (Amended) A cancer vaccine according to claim 31, having part of a nucleic acid sequence as shown in Fig. 10 or Fig.

Please add new claims 33 through 36, as follows:

33. (New) A cancer vaccine according to claim 1, which is a therapeutic vaccine.

mb
DT 7
34. (New) A cancer vaccine according to claim 1, wherein said T cell epitope is a T cell epitope of said polypeptide of the CD55 family.

C
35. (New) A cancer vaccine according to claim 1, wherein the T cell response is one or more of an antigen specific proliferation responses, a T-helper cell response, a cytotoxic T-cell responses, enhanced IL-2 production, induction of CD45RO cells, infiltration of CD4, CD8 and CD56 cells within the tumors of immunised patients, enhanced natural killer activity, autologous tumor killing which is unrelated to NK killing, and raising CTL antibodies that neutralize CD55 and allow complement mediated lysis to take place.

36. (New) A cancer vaccine according to claim 1, wherein the T cell response is one or more of a T-helper cell response, a cytotoxic T cell response and a NK cell response.

Please cancel claim 3 without prejudice.